Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Crizotinib in High-Risk Uveal Melanoma
NCT02223819Phase 2Completed
- Sponsor
- Columbia University
- Start
- Mar 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of crizotinib in Uveal melanoma (UM), sponsored by Columbia University. Started Mar 2015; status: completed.
02
Drugs
crizotinib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02223819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223819.